|
Video: What is a Stock Split?
|
|
Veru is a biopharmaceutical company. Co.'s infectious disease clinical development program includes: COVID-19 patients at risk for acute respiratory distress syndrome; and Sabizabulin, a microtubule disruptor. Co.'s oncology clinical development program includes: breast cancer, which consist of Enobosarm, a selective androgen receptor and Sabizabulin, a microtubule disruptor; and prostate cancer, which include Sabizabulin, a microtubule disruptor, VERU-100, a GnRH antagonist depot and Zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist. Co.'s sexual health program include ENTADFI, for the treatment of benign prostatic hyperplasia. According to our Veru stock split history records, Veru has had 0 splits. | |
|
Veru (VERU) has 0 splits in our Veru stock split history database.
Looking at the Veru stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Veru shares, starting with a $10,000 purchase of VERU, presented on a split-history-adjusted basis factoring in the complete Veru stock split history.
Growth of $10,000.00
With Dividends Reinvested
|
Start date: |
04/21/2014 |
|
End date: |
04/16/2024 |
|
Start price/share: |
$7.57 |
|
End price/share: |
$1.25 |
|
Starting shares: |
1,321.00 |
|
Ending shares: |
1,333.32 |
|
Dividends reinvested/share: |
$0.07 |
|
Total return: |
-83.33% |
|
Average Annual Total Return: |
-16.41% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,667.13 |
|
Years: |
9.99 |
|
|
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/21/2014 |
|
End date: |
04/16/2024 |
|
Start price/share: |
$7.57 |
|
End price/share: |
$1.25 |
|
Dividends collected/share: |
$0.07 |
|
Total return: |
-82.56% |
|
Average Annual Total Return: |
-16.03% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,744.45 |
|
Years: |
9.99 |
|
|
|
|
|